Why Gilead Sciences Could Gain 30%
September 19, 2014 at 13:13 PM EDT
Citigroup’s Yaron Werber and team upped their price target on Gilead Sciences (GILD) to $139 from $111. They explain why: Associated Press From our discussions with mgt, Gilead looks very optimistic about FY15 and anticipates that hepC treatment volumes could be up substantially over FY14 rates globally. This will be driven by the availability of [...]
